LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...

Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...

Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...

HOUSTON, TX / ACCESS Newswire / July 9, 2025 / Mann Eye Institute, a leader in innovative eye care since the 1970s, is proud ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases ...

Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD ...

Company News Published 07/07/2025, 08:10 AM 0 Alcon to acquire LumiThera and its dry AMD light therapy device ALC -1.70% ...

See disclosure here or remove ads. The acquisition does not include LumiThera’s diagnostic devices, which will be separated and spun off to LumiThera’s shareholders prior to the acquisition. Subject ...